Sign In   |   Register
EAS-FHSC Symposium on FH - Preliminary Programme
Friday, November 25, 2016

12.00 onwards

Arrival, registration


Opening & Welcome
M Banach (PL), M Vrablík (CZ), K Ray (UK), A Catapano (IT)

Session 1:

Familial hypercholesterolaemia in 2016: from epidemiology to diagnosis


Role of lipids in the atherogenesis: the case of FH
Speaker: G Latskovits (LAT)


Epidemiology and clinical picture of FH
Speaker: M Gruchala (PL)
Commentator: M Ezhov (RU)


Genetics of FH: FH is not a single disease
Speaker: JA Kuivenhoven (NL)
Commentator: B Vohnout (SK)


Diagnostic criteria for FH (DLNC, Simone Broom, MedPed)
Speaker: M Vrablík (CZ)
Commentator: D Pella (SK)

 Session 2

Groupwork: case presentations and discussion


Case presentations and group discussions (4 groups with 2 Experts/Chairs in each; the same cases and presentations in each group)
Group 1: M Banach (PL), Z Fras (SLO)
Group 2: M Vrablík (CZ), H Soran (UK)
Group 3: K Ray (UK), M Ezhov (RU)
Group 4: A Catapano (IT), G Latskovits (LAT)

Saturday, November 26, 2016

Session 3

Current FH screening activities


Screening for FH: universal, opportunistic or cascade screening?
Speaker: S Romeo (SWE)
Commentator: Z Fras (SLO)


Collaborative efforts in FH identification: THE FHSC INITIATIVE
Speaker: K Ray (UK)
Commentator: R Ceska (CZ)


Registries: from set up to practical problems
Speaker: G.K. Hovingh (NL)
Commentator: G Latskovits (LAT)

  11.30 Current guidelines for FH treatment: EAS consensus papers
Speaker: A Catapano (IT)
Commentator: M Viigmaa (LIT)

  12.30 Lunch
Session 4 Therapeutic consideration for FH patients in 2016 and beyond
  13.30 Real challenge in the optimal therapy: statin non-response, non-adherence, statin discontinuation
Speaker: M Banach (PL)
Commentator: D Gaita (RO)


LDL-apheresis vs new drugs (PCSK9 inhibitors) - when, whom, why?
Speaker: H Soran (UK)
Commentator: A Rynkiewicz (PL)

  15.00 FH in special populations: children
Speaker: TBC
Commentator: M Kayikcioglu (TK)

  15.45 Coffee break
Session 5 Workshops: Special chapters of FH management
  16.00-18.30 Workshops (group divided into 3 parts, rotating in 45 minutes; 2 experts in each group)
    - FH management in statin intolerance
M Banach (PL), M Averna (IT)
    - CVD risk assessment in FH: are all the FH patients created equal?
K Ray (UK), E Moses (GR)
    - Management of FH in special populations (pregnancy, children, concomitant diseases)
H Soran (UK)
D Lighezan (RO)
Sunday, November 27, 2016
Session 6 08.00-09.30 Central & European Countries Key Opinion Leader Summit
A Catapano (IT), M Kayikcioglu (TK), E Michenko (UKR), E Mirrakhimov (KYR), B Pojskic (BOSNIA), A Shek (RUS), M Viigimaa (LIT), K Lalic (SER)
Session 7 Severe and Severe and homozygous FH
  09.30 Severe FH: diagnosis and management
Speaker: T Freiberger (CZ)
Commentator: A Susekov (RU)
  10.15 Identification and management of homozygous FH
Speaker: M Averna (IT)
Commentator: B Vohnout (SK)


Imaging of atherosclerosis in FH
Speaker: L Tokgozoglu (TK)
Commentator: K Ray (UK)

  12.00-13:00 Conclusion and Take Home Message
A Catapano (IT), K Ray (UK), M Banach (PL), M Vrablík (CZ)
Membership Software Powered by®  ::  Legal